FR2891273B1 - NOUVEAUX DERIVES BENZIMIDAZOLES ET BENZOTHIAZOLES, LEUR PREPARATION ET LEUR UTILISATION PHARMACEUTIQUE NOTAMMENT COMME INHIBITEURS DE CMet - Google Patents

NOUVEAUX DERIVES BENZIMIDAZOLES ET BENZOTHIAZOLES, LEUR PREPARATION ET LEUR UTILISATION PHARMACEUTIQUE NOTAMMENT COMME INHIBITEURS DE CMet

Info

Publication number
FR2891273B1
FR2891273B1 FR0509850A FR0509850A FR2891273B1 FR 2891273 B1 FR2891273 B1 FR 2891273B1 FR 0509850 A FR0509850 A FR 0509850A FR 0509850 A FR0509850 A FR 0509850A FR 2891273 B1 FR2891273 B1 FR 2891273B1
Authority
FR
France
Prior art keywords
preparation
pharmaceutical use
benzothiazole derivatives
novel benzimidazole
cmet inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0509850A
Other languages
English (en)
Other versions
FR2891273A1 (fr
Inventor
Conception Nemecek
Francois Clerc
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0509850A priority Critical patent/FR2891273B1/fr
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Priority to AU2006296468A priority patent/AU2006296468B2/en
Priority to ZA200802447A priority patent/ZA200802447B/xx
Priority to PCT/FR2006/002183 priority patent/WO2007036630A1/fr
Priority to CNA2006800355055A priority patent/CN101273019A/zh
Priority to JP2008532821A priority patent/JP2009510033A/ja
Priority to EP06808199A priority patent/EP1934187A1/fr
Priority to SG201006691-8A priority patent/SG165381A1/en
Priority to EA200800947A priority patent/EA014315B1/ru
Priority to NZ566568A priority patent/NZ566568A/en
Priority to ARP060104155A priority patent/AR056528A1/es
Priority to CA002620857A priority patent/CA2620857A1/fr
Priority to KR1020087007348A priority patent/KR20080050438A/ko
Priority to BRPI0616754-3A priority patent/BRPI0616754A2/pt
Priority to TW095135816A priority patent/TW200745048A/zh
Priority to UY29814A priority patent/UY29814A1/es
Publication of FR2891273A1 publication Critical patent/FR2891273A1/fr
Publication of FR2891273B1 publication Critical patent/FR2891273B1/fr
Application granted granted Critical
Priority to IL189961A priority patent/IL189961A0/en
Priority to US12/054,719 priority patent/US8110571B2/en
Priority to NO20081944A priority patent/NO20081944L/no
Priority to MA30876A priority patent/MA29922B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C07D235/32—Benzimidazole-2-carbamic acids, unsubstituted or substituted; Esters thereof; Thio-analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
FR0509850A 2005-09-27 2005-09-27 NOUVEAUX DERIVES BENZIMIDAZOLES ET BENZOTHIAZOLES, LEUR PREPARATION ET LEUR UTILISATION PHARMACEUTIQUE NOTAMMENT COMME INHIBITEURS DE CMet Expired - Fee Related FR2891273B1 (fr)

Priority Applications (20)

Application Number Priority Date Filing Date Title
FR0509850A FR2891273B1 (fr) 2005-09-27 2005-09-27 NOUVEAUX DERIVES BENZIMIDAZOLES ET BENZOTHIAZOLES, LEUR PREPARATION ET LEUR UTILISATION PHARMACEUTIQUE NOTAMMENT COMME INHIBITEURS DE CMet
KR1020087007348A KR20080050438A (ko) 2005-09-27 2006-09-25 신규 벤즈이미다졸 및 벤조티아졸 유도체, 이들의 제조방법, 약물로서의 이들의 용도, 제약 조성물, 및 특히ｃ-ｍｅｔ 억제제로서의 신규 용도
PCT/FR2006/002183 WO2007036630A1 (fr) 2005-09-27 2006-09-25 Derives de benzimidazoles et benzothiazoles et leur utilisation en tant qu'inhibiteurs de kinases notamment de met
CNA2006800355055A CN101273019A (zh) 2005-09-27 2006-09-25 新的苯并咪唑和苯并噻唑衍生物，它们的制备方法，作为药物的应用，药物组合物和特别地作为C－Met抑制剂的新用途
JP2008532821A JP2009510033A (ja) 2005-09-27 2006-09-25 新規ベンゾイミダゾール及びベンゾチアゾール誘導体、その調製方法、薬物としてのその使用、薬剤組成物、並びに特にｃ−ｍｅｔ阻害剤としての新規使用
EP06808199A EP1934187A1 (fr) 2005-09-27 2006-09-25 Derives de benzimidazoles et benzothiazoles et leur utilisation en tant qu'inhibiteurs de kinases notamment de met
SG201006691-8A SG165381A1 (en) 2005-09-27 2006-09-25 Novel benzimidazole and benzothiazole derivatives, method for preparing same, use thereof as drugs, pharmaceutical compositions and novel use in particular as c-met inhibitors
ZA200802447A ZA200802447B (en) 2005-09-27 2006-09-25 Novel benzimidazole and benzothiazole derivatives, method for preparing same, use thereof as drugs, pharmaceutical compositions and novel use in particular as C-MET inhibitors
NZ566568A NZ566568A (en) 2005-09-27 2006-09-25 Novel benzimidazole and benzothiazole derivatives, method for preparing same, use thereof as drugs, pharmaceutical compositions and novel use especially as C-Met inhibitors
ARP060104155A AR056528A1 (es) 2005-09-27 2006-09-25 Derivados de bencimidazoles y benzotiazoles su proceso de preparacion su aplicacion como medicamentos composiciones farmaceuticas y utilizacion principalmente como inhibidores de cmet
AU2006296468A AU2006296468B2 (en) 2005-09-27 2006-09-25 Novel benzimidazole and benzothiazole derivatives, method for preparing same, use thereof as drugs, pharmaceutical compositions and novel use in particular as C-Met inhibitors
CA002620857A CA2620857A1 (fr) 2005-09-27 2006-09-25 Derives de benzimidazoles et benzothiazoles et leur utilisation en tant qu'inhibiteurs de kinases notamment de met
EA200800947A EA014315B1 (ru) 2005-09-27 2006-09-25 НОВЫЕ ПРОИЗВОДНЫЕ БЕНЗИМИДАЗОЛОВ И БЕНЗОТИАЗОЛОВ, СПОСОБ ИХ ПОЛУЧЕНИЯ, ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕКАРСТВЕННЫХ СРЕДСТВ, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И НОВОЕ ПРИМЕНЕНИЕ, В ЧАСТНОСТИ, В КАЧЕСТВЕ ИНГИБИТОРОВ Cmet
BRPI0616754-3A BRPI0616754A2 (pt) 2005-09-27 2006-09-25 derivados de benzimidazóis e benzotiazóis, o respectivo processo de preparo, respectivos medicamentos, composições farmacêuticas e utilização
TW095135816A TW200745048A (en) 2005-09-27 2006-09-27 Novel benzimidazole and benzothiazole derivatives, preparation process therefor, application thereof as medicaments, pharmaceutical compositions and novel use especially as CMET inhibitors
UY29814A UY29814A1 (es) 2005-09-27 2006-09-27 Derivados nuevos de bencimidazoles y benzotiazoles, su proceso de preparación, su aplicación como medicamentos, composiciones farmacéuticas y utilización nueva principalmente como inhibidores de cmet
IL189961A IL189961A0 (en) 2005-09-27 2008-03-05 Novel benzimidazole and benzothiazole derivatives, method for preparing same, use thereof as drugs, pharmaceutical compositions and novel use in particular as c-met inhibitors
US12/054,719 US8110571B2 (en) 2005-09-27 2008-03-25 Benzimidazole and benzothiazole derivatives, method for preparing same, use thereof as drugs, pharmaceutical compositions and novel use especially as c-MET inhibitors
NO20081944A NO20081944L (no) 2005-09-27 2008-04-23 Nye benzimidazol- og benzothiazolderivater, fremgangsmate for fremstilling, anvendelse derav som legemiddel, samt farmasoytiske sammensetninger og ny anvendelse spesielt som C-Met inhibitorer
MA30876A MA29922B1 (fr) 2005-09-27 2008-04-24 NOUVEAUX DERIVES DE BENZIMIDAZOLES ET BENZOTHIAZOLES, LEUR PROCEDE DE PREPARATION, LEUR APPLICATION A TITRE DE MEDICAMENTS, COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE CMet

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0509850A FR2891273B1 (fr) 2005-09-27 2005-09-27 NOUVEAUX DERIVES BENZIMIDAZOLES ET BENZOTHIAZOLES, LEUR PREPARATION ET LEUR UTILISATION PHARMACEUTIQUE NOTAMMENT COMME INHIBITEURS DE CMet

Publications (2)

Publication Number Publication Date
FR2891273A1 FR2891273A1 (fr) 2007-03-30
FR2891273B1 true FR2891273B1 (fr) 2007-11-23

Family

ID=35911217

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0509850A Expired - Fee Related FR2891273B1 (fr) 2005-09-27 2005-09-27 NOUVEAUX DERIVES BENZIMIDAZOLES ET BENZOTHIAZOLES, LEUR PREPARATION ET LEUR UTILISATION PHARMACEUTIQUE NOTAMMENT COMME INHIBITEURS DE CMet

Country Status (20)

Country Link
US (1) US8110571B2 (fr)
EP (1) EP1934187A1 (fr)
JP (1) JP2009510033A (fr)
KR (1) KR20080050438A (fr)
CN (1) CN101273019A (fr)
AR (1) AR056528A1 (fr)
AU (1) AU2006296468B2 (fr)
BR (1) BRPI0616754A2 (fr)
CA (1) CA2620857A1 (fr)
EA (1) EA014315B1 (fr)
FR (1) FR2891273B1 (fr)
IL (1) IL189961A0 (fr)
MA (1) MA29922B1 (fr)
NO (1) NO20081944L (fr)
NZ (1) NZ566568A (fr)
SG (1) SG165381A1 (fr)
TW (1) TW200745048A (fr)
UY (1) UY29814A1 (fr)
WO (1) WO2007036630A1 (fr)
ZA (1) ZA200802447B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2868421B1 (fr) 2004-04-01 2008-08-01 Aventis Pharma Sa Nouveaux benzothiazoles et leur utilisation comme medicaments
FR2922550B1 (fr) * 2007-10-19 2009-11-27 Sanofi Aventis Nouveaux derives de 6-aryl/heteroalkyloxy benzothiazole et benzimidazole, application comme medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de cmet
EP2483407A2 (fr) 2009-09-30 2012-08-08 President and Fellows of Harvard College Procédés de modulation de l'autophagie par la modulation de produits géniques renforçant l'autophagie
KR20160024639A (ko) 2014-08-26 2016-03-07 삼성전자주식회사 c-Met 표적 치료제의 저항성 또는 효능 예측을 위한 바이오마커 PDGF
WO2020188015A1 (fr) 2019-03-21 2020-09-24 Onxeo Molécule dbait associée à un inhibiteur de kinase pour le traitement du cancer
AU2020378630A1 (en) 2019-11-08 2022-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2541752A1 (de) * 1975-09-19 1977-03-24 Hoechst Ag Anthelminthisch wirksame 2-carbalkoxyamino-5(6)-phenyl-sulfonyloxy- benzimidazole und verfahren zu ihrer herstellung
JPS5914027B2 (ja) * 1976-02-27 1984-04-02 ヘキスト・アクチ−エンゲゼルシヤフト ２−カルボアルコキシアミノ−５（６）−フエニルスルホニルオキシ−ベンズイミダゾ−ル化合物
DE3247615A1 (de) * 1982-12-23 1984-07-05 Hoechst Ag, 6230 Frankfurt Substituierte phenylsulfonyloxybenzimidazolcarbaminate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
FR2751649B1 (fr) * 1996-07-26 1998-08-28 Adir Nouveaux derives de benzimidazole, de benzoxazole et de benzothiazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB9900752D0 (en) * 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
WO2001057008A1 (fr) * 2000-02-07 2001-08-09 Abbott Gesellschaft Mit Beschrankter Haftung & Company Kommanditgesellschaft Derives de 2-benzothiazolyle uree et leur utilisation en tant qu'inhibiteurs de proteine kinase
US6693125B2 (en) * 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
US20050038022A1 (en) * 2001-03-26 2005-02-17 Unisearch Limited Method for treatment of cancer and compositions for use therein
EP1298125A1 (fr) * 2001-09-26 2003-04-02 Aventis Pharma S.A. Benzimidazoles substitués et leur usage comme traitement du cancer
FR2868421B1 (fr) * 2004-04-01 2008-08-01 Aventis Pharma Sa Nouveaux benzothiazoles et leur utilisation comme medicaments

Also Published As

Publication number Publication date
WO2007036630A1 (fr) 2007-04-05
TW200745048A (en) 2007-12-16
US20080194555A1 (en) 2008-08-14
AU2006296468A1 (en) 2007-04-05
JP2009510033A (ja) 2009-03-12
CN101273019A (zh) 2008-09-24
NZ566568A (en) 2012-05-25
BRPI0616754A2 (pt) 2011-06-28
FR2891273A1 (fr) 2007-03-30
ZA200802447B (en) 2009-08-26
EP1934187A1 (fr) 2008-06-25
KR20080050438A (ko) 2008-06-05
EA014315B1 (ru) 2010-10-29
NO20081944L (no) 2008-06-19
EA200800947A1 (ru) 2009-02-27
CA2620857A1 (fr) 2007-04-05
UY29814A1 (es) 2007-04-30
US8110571B2 (en) 2012-02-07
SG165381A1 (en) 2010-10-28
AR056528A1 (es) 2007-10-10
MA29922B1 (fr) 2008-11-03
AU2006296468B2 (en) 2012-10-18
IL189961A0 (en) 2008-08-07

Similar Documents

Publication Publication Date Title
FR2922550B1 (fr) Nouveaux derives de 6-aryl/heteroalkyloxy benzothiazole et benzimidazole, application comme medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de cmet
ES2439244T8 (es) Inhibidores de serina proteasa tipo tripsina, su preparación y uso
HK1125368A1 (en) Chromane substituted benzimidazoles and their use as acid pump inhibitors
BRPI0720124A2 (pt) Composições farmacêuticas e seus métodos de uso.
DK3421471T3 (da) Purin- og deazapurinderivater som farmaceutiske forbindelser
CR10743A (es) Derivados de azaadamantano y metodos de uso de los mismos
BRPI0821499A2 (pt) Artigos de filtração de fluído e métodos de preparo e uso dos mesmos
FR2891273B1 (fr) NOUVEAUX DERIVES BENZIMIDAZOLES ET BENZOTHIAZOLES, LEUR PREPARATION ET LEUR UTILISATION PHARMACEUTIQUE NOTAMMENT COMME INHIBITEURS DE CMet
PL1861387T3 (pl) Pochodne benzoimidazolu i ich kompozycje farmaceutyczne
FR2903985B1 (fr) Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
CR10709A (es) Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
BRPI0808013A2 (pt) Compostos de quinoxalina e uso dos mesmos
BRPI0812909A2 (pt) Derivados de guanina policíclica e métodos de uso dos mesmos.
BRPI0808025A2 (pt) Composto de benzimidazol e uso farmacêutico do mesmo
BRPI0821558A2 (pt) virus da estomatite vesicular atenuado geneticamente modificado, ecomposições e métodos de uso dessas
FR2896504B1 (fr) Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
BRPI0909954A2 (pt) "diazacarbazóis e métodos de uso"
MA28941B1 (fr) Nouveaux derives bis-azaindoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
BRPI0907236A2 (pt) inibidores de proteína quinase e uso dos mesmos
SMT201300080B (it) Derivati di carbammati di alchiltiazoli, loro preparazione e loro utilizzo come inibitori dell'enzima faah
BRPI0808054A2 (pt) análogos de indenoisoquinolinona e métodos de uso dos mesmos
BRPI0915527A2 (pt) pepitídeos, composição farmacêutica e exossomos compreendendo os mesmos, métodos e usos
BRPI0907706A2 (pt) Composto, uso do dito composto e composição farmacéutica compreendendo o dito composto
BRPI0720323A2 (pt) composto, método de tratamento, composição farmacêutica e uso do composto
FR2907120B1 (fr) Nouveaux derives imidazolones,leur preparation a titre de medicaments,compositions pharmaceutiques,utilisation comme inhibiteurs de proteines kinases notamment cdc7

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20140530